287 related articles for article (PubMed ID: 32884290)
1. Cervical Cancer: Emerging Immune Landscape and Treatment.
Guo L; Hua K
Onco Targets Ther; 2020; 13():8037-8047. PubMed ID: 32884290
[TBL] [Abstract][Full Text] [Related]
2. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
3. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
4. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
5. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.
Wei Y; Zhao Q; Gao Z; Lao XM; Lin WM; Chen DP; Mu M; Huang CX; Liu ZY; Li B; Zheng L; Kuang DM
J Clin Invest; 2019 May; 129(8):3347-3360. PubMed ID: 31112529
[TBL] [Abstract][Full Text] [Related]
6. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
7. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
8. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.
Wang Y; Li G
Front Med; 2019 Aug; 13(4):438-450. PubMed ID: 30826965
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
13. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.
Duranti S; Pietragalla A; Daniele G; Nero C; Ciccarone F; Scambia G; Lorusso D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925884
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
15. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer.
Shibata T; Lieblong BJ; Sasagawa T; Nakagawa M
Cancer Treat Rev; 2019 Aug; 78():8-16. PubMed ID: 31302573
[TBL] [Abstract][Full Text] [Related]
16. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.
Meng Y; Liang H; Hu J; Liu S; Hao X; Wong MSK; Li X; Hu L
J Cancer; 2018; 9(16):2938-2945. PubMed ID: 30123362
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
20. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]